In this webinar, discover how to get the most out of your patient engagement programs while protecting your brand from regulatory non-compliance.

This webinar roundtable explores interesting technologies, the scientific issues, the clinical opportunities for developing multivalent biologics platforms, whether certain technologies, such as antibodies, their fragments, or non-antibody scaffolds, are superior to others, the pros and cons of such bispecifics for improving management of patients, and licensing and commercial strategies.

In this whitepaper, our guest experts reveal how to avoid the seven top M&A deal killers.

In this webinar, Patrick Stroth of Rubicon M&A Insurance Services dives into the role representations and warranties insurance will play in your next M&A transaction.

This all-purpose due diligence checklist contains a list of all the standard documents any buyer or partner might want to see.
.

In this whitepaper, learn what is artificial intelligence and how is it being applied to drug discovery, and much more.

In this whitepaper, Linda Pullan provides licensing negotiations insights from a biotech business development perspective.

This white paper covers when to consider using suppliers, key differences between standard / OTS and custom part suppliers, tools and methods for managing suppliers, and when and how to transition between suppliers and internal resources.

This whitepaper evaluates the regulations that support GDP, best practices on how document contributors can apply the golden rule of research to their TMF, how to avoid writing too many and unnecessary Note-to-Files (NTFs), and tips on becoming inspection ready and staying that way.

In this whitepaper, explore the nuances of valuation, its framework and the processes for getting it right.

This whitepaper gives medical groups, life sciences, and healthcare companies in the lower middle market an understanding of financing and M&A alternatives available, the role of financial buyers, key issues around selling equity in your business, and the typical financing and M&A process.

In this whitepaper, biopharma partnering expert and Life Sciences consultant, Linda Pullan, PhD, explores the current oncology landscape and offers insightful perspective on trends, pipeline by indication, dealmaking, and the top ten oncology companies and the drugs they’re developing.